Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Atara Biotherapeutics, Inc.
Bear Case (25th pct.)
129.7% vs price
Base Case (Median)
144.0% vs price
Bull Case (75th pct.)
158.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| EV/EBITDA | $25.57 | 172.6% | Medium (20%) |
| Earnings Power Value | $20.21 | 115.4% | Medium (50%) |
Based on 2 out of 7 methods, ATRA appears undervalued at the current price of $9.38. The base case fair value of $22.89 implies 144.0% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.